Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
34
YMAB Quote, Financials, Valuation and Earnings
Last price:
$4.33
Seasonality move
:
-4.07%
Day range:
$4.20 - $4.39
52-week range:
$3.55 - $16.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.19x
P/B ratio:
2.20x
Volume:
181.7K
Avg. volume:
183.4K
1-year change:
-66.74%
Market cap:
$197M
Revenue:
$87.7M
EPS (TTM):
-$0.64
Analysts' Opinion
-
Consensus RatingY-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $14.70, Y-mAbs Therapeutics has an estimated upside of 237.93% from its current price of $4.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $4.35.
Fair Value
-
According to the consensus of 8 analysts, Y-mAbs Therapeutics has 237.93% upside to fair value with a price target of $14.70 per share.
YMAB vs. S&P 500
-
Over the past 5 trading days, Y-mAbs Therapeutics has underperformed the S&P 500 by -2.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Y-mAbs Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Y-mAbs Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Y-mAbs Therapeutics reported revenues of $20.9M.
Earnings Growth
-
Y-mAbs Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Y-mAbs Therapeutics reported earnings per share of -$0.12.
Enterprise value:
136.7M
EV / Invested capital:
--
Price / LTM sales:
2.19x
EV / EBIT:
--
EV / Revenue:
1.54x
PEG ratio (5yr expected):
-0.22x
EV / Free cash flow:
-7.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$72.6M
Return On Assets:
-22.74%
Net Income Margin (TTM):
-31.85%
Return On Equity:
-30.14%
Return On Invested Capital:
-30.14%
Operating Margin:
-31.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $75M | $84.5M | $88.7M | $19.9M | $20.9M | |
| Gross Profit | $67.2M | $73.1M | $72.6M | $17.8M | $17.9M | |
| Operating Income | -$74.6M | -$25.1M | -$30.8M | -$6.9M | -$6.5M | |
| EBITDA | -$73.8M | -$24.4M | -$30.4M | -$6.7M | -$6.5M | |
| Diluted EPS | -$1.69 | -$0.49 | -$0.64 | -$0.15 | -$0.12 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $264M | $177.7M | $124M | $108.3M | $90.4M | |
| Total Assets | $274.9M | $191M | $137.4M | $123.3M | $112.6M | |
| Current Liabilities | $17M | $29M | $25.9M | $17.6M | $19M | |
| Total Liabilities | $22.7M | $33.6M | $29.6M | $24.1M | $23.2M | |
| Total Equity | $252.2M | $157.5M | $107.8M | $99.2M | $89.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$64.1M | -$17.6M | -$19.1M | -$3.5M | -$6.9M | |
| Cash From Investing | -- | -- | -$127K | -- | -$127K | |
| Cash From Financing | $52K | $688K | $3.8M | $588K | $114K | |
| Free Cash Flow | -$64.1M | -$17.6M | -$19.3M | -$3.5M | -$7M | |
YMAB
Sector
Market Cap
$197M
$34.4M
Price % of 52-Week High
27%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-66.74%
-37.36%
Beta (5-Year)
0.506
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.34
200-day SMA
Sell
Level
$7.54
Bollinger Bands (100)
Sell
Level
4.17 - 5.13
Chaikin Money Flow
Sell
Level
-87.8K
20-day SMA
Sell
Level
$4.51
Relative Strength Index (RSI14)
Sell
Level
46.01
ADX Line
Buy
Level
22.13
Williams %R
Neutral
Level
-71.2644
50-day SMA
Sell
Level
$4.47
MACD (12, 26)
Buy
Level
1.18
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
50.6K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5089)
Buy
CA Score
(Annual)
Level (-0.0422)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.3838)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Stock Forecast FAQ
In the current month, YMAB has received 7 Buy ratings 0 Hold ratings, and 1 Sell ratings. The YMAB average analyst price target in the past 3 months is $14.70.
-
Where Will Y-mAbs Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Y-mAbs Therapeutics share price will rise to $14.70 per share over the next 12 months.
-
What Do Analysts Say About Y-mAbs Therapeutics?
Analysts are divided on their view about Y-mAbs Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Y-mAbs Therapeutics is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Y-mAbs Therapeutics's Price Target?
The price target for Y-mAbs Therapeutics over the next 1-year time period is forecast to be $14.70 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is YMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Y-mAbs Therapeutics is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of YMAB?
You can purchase shares of Y-mAbs Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Y-mAbs Therapeutics shares.
-
What Is The Y-mAbs Therapeutics Share Price Today?
Y-mAbs Therapeutics was last trading at $4.33 per share. This represents the most recent stock quote for Y-mAbs Therapeutics. Yesterday, Y-mAbs Therapeutics closed at $4.35 per share.
-
How To Buy Y-mAbs Therapeutics Stock Online?
In order to purchase Y-mAbs Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
